CT-P13: Clinical Trials

7 trials of CT-P13, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 enrolling by invitation, 1 recruiting, 1 terminated. 7 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 47Completed 3, Enrolling by invitation 1, Recruiting 1, Terminated 1, Unknown 1

Follow CT-P13: new trials by email Literature Review of CT-P13 trials Research Report on CT-P13

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease
TDM-based infliximab intravenous therapy, Standard infliximab intravenous therapy - Crohn Disease, Infliximab
Phase 4RecruitingAsan Medical Center862023-11-012024-05-14
Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis
Remsima - Psoriasis
Phase 4CompletedGhurki Trust and Teaching Hospital512022-03-102023-09-21
REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)
Adalimumab and its biosimilars, Biological: Etanercept and its biosimilars, Golimumab - Ankylosing Spondylitis, Axial Spondyloarthritis
Phase 4UnknownHanyang University Seoul Hospital4482022-01-152021-12-20
Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)
Infliximab CT-P13, Immunosuppressors (Thiopurines or Methotrexate) - Crohn Disease
Phase 4CompletedGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives2132021-12-212026-11-06
De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease
Infliximab, Adalimumab - Inflammatory Bowel Diseases, Crohn Disease
Phase 4Enrolling by invitationUniversity Medical Center Groningen1482021-03-112025-01-06
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
Infliximab - Colitis, Ulcerative
Phase 4TerminatedAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)502019-09-042025-02-06
The NOR-SWITCH Study
Innovator infliximab, Biosimilar infliximab - Rheumatoid Arthritis, Spondyloarthritis
Phase 4CompletedDiakonhjemmet Hospital4822014-10-012017-09-25

Conditions studied

Crohn Disease (4)  ·  Colitis, Ulcerative (3)  ·  Arthritis, Psoriatic (1)  ·  Arthritis, Rheumatoid (1)  ·  Axial Spondyloarthritis (1)  ·  Inflammatory Bowel Diseases (1)  ·  Psoriasis (1)  ·  Spondylarthritis (1)  ·  Spondylitis, Ankylosing (1)

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Asan Medical Center (1)  ·  Diakonhjemmet Hospital (1)  ·  Ghurki Trust and Teaching Hospital (1)  ·  Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (1)  ·  Hanyang University Seoul Hospital (1)  ·  University Medical Center Groningen (1)

Countries

Netherlands (2)  ·  Norway (2)  ·  Belgium (1)  ·  France (1)  ·  Ireland (1)  ·  Pakistan (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Byong Duk Ye, MD, PhD (1)  ·  Dr. Faria Asad (1)  ·  Dr. Nabigha Khalid (1)  ·  Dr. Saleha Batool (1)  ·  Dr. Sumera Hanif (1)  ·  Dr. Talat Masood Akbar (1)  ·  Geert DHaens (1)  ·  Patrick F van Rheenen, MD PhD (1)  ·  Prof. Dr. Haroon Nabi (1)  ·  Tae-Hwan Kim, MD, PhD (1)  ·  Tore K. Kvien, MD PhD (1)

Results publications

PMID 28502609, PMID 30762274, PMID 32965617, PMID 34732500, PMID 39390697

NIH funding

2014 (1)